Neuroscience
EGFR mutations in lung cancer may predict sensitivity to gefitinib therapy
Published in Cancer Gene Therapy Week, July 19th, 2004
"Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States," scientists in the United States report.
"Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week
More Articles from Cancer Gene Therapy Week
- Cancer Therapy
Tissue-specific promoters ensure oncolytic viruses target cancer tissues - Clinical Trials
Receptor deficiency stalls the efforts of lung cancer gene therapy - Colon Cancer
The Cre/lox system helps Wnt-targeted gene therapy destroy colorectal cancer - Genetic Engineering
Mutant insulin-like growth factor receptor reduces tumor growth and invasion - Cervical Cancer
FRET inhibition effective for measuring AS-ODN activity in vivo - Collaborations
Immusol initiates collaboration to advance oncology drug-discovery efforts - More from this issue of Cancer Gene Therapy Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
